AKT1 and Alzheimer disease: This research identified 12 ingredients of FRP treatment of AD by targeting 235 targets via multiple pathways, which were concentrated on the neuroactive ligand-receptor interaction, PI3K-Akt, calcium signaling, and cAMP signaling pathways.